Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas

Presented by:
Ann S. LaCasce
Search for other papers by Ann S. LaCasce in
Current site
Google Scholar
PubMed Close
 MD, MMSc
and
Ariela Noy
Search for other papers by Ariela Noy in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 20: Issue 5.5
Online Publication Date:
02 Jun 2022
DOI:
https://doi.org/10.6004/jnccn.2022.5015
Restricted access

Although follicular lymphoma (FL) and marginal zone lymphoma (MZL) share similarities, the 2 diseases have distinct biologic differences that affect their presentation and treatment. Stage I disease is more common in MZL than in FL due to marginal zone biology, for example, and stage I MZL is curable by surgery or radiation therapy. Newer therapies for both FL and MZL provide chemotherapy-free options, but they are not identical. Brüton’s tyrosine kinase inhibitors are active in relapsed or refractory MZL but not in FL, for example. CAR T-cell therapy has just been approved for treatment of FL and is an ongoing area of investigation for both diseases.

Disclosures: Dr. LaCasce has disclosed serving on the product/speakers bureau for Research to Practice. Dr. Noy has disclosed serving as a scientific advisor for ADC Therapeutics, Epizyme, EUSA, Janssen Pharmaceutica Products, LP, MorphoSys AG, and TG Therapeutics; receiving honoraria from Medscape and Pharmacyclics; receiving consulting fees from Physicians' Education Resource; and receiving grant/research support from Rafael Pharma.

Correspondence: Ann S. LaCasce, MD, MMSc, Dana-Farber Cancer Institute, 450 Brookline Avenue, M227, Boston, MA 02215. Email: alacasce@partners.org; and Ariela Noy, MD, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Email: noya@mskcc.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 2.2022. Accessed March 20, 2022. To view the most recent version, visit NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37:1188–1199.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    TG Therapeutics announces voluntary withdrawal of the BLA/sNDA for U2 to treat patients with CLL and SLL [press release]. Morrisville, NC: Associated Press; April 15, 2022.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma [published correction in J Clin Oncol 2018;36:521]. J Clin Oncol 2017;35:3898–3905.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Matasar MJ, Capra M, Özcan M, et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial [published correction in Lancet Oncol 2021; 22:e239]. Lancet Oncol 2021;22:678–689.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39:1609–1618.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Bollard J, Massoma P, Vercherat C, et al. The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors. Oncotarget 2015;6:36731–36745.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433–1442.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23:91–103.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017;129:2224–2232.

  • 11.

    Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv 2020;4:5773–5784.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. Clin Cancer Res 2021;27:6323–6332.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020;136:2038–2050.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Song Y, Zhou K, Zou DH, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study [published online March 18, 2022]. Blood, doi: 10.1182/blood.2021014162

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Lansigan F, Andorsky DJ, Coleman M, et al. Completed induction phase analysis of MAGNIFY: phase 3b study of lenalidomide + rituximab (R 2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma. Blood 2021;138(Suppl 1):812.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open label, registration directed phase II study [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 7506.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2022 by the National Comprehensive Cancer Network 2022
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2022
Online Publication Date:
02 Jun 2022

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2590 923 139
PDF Downloads 1331 258 11
EPUB Downloads 0 0 0